Giles Campion
Geen lopende functies
Vermogen: 79 200 $ op 31-07-2023
Loopbaan van Giles Campion
Eerdere bekende functies van Giles Campion
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SILENCE THERAPEUTICS PLC | Directeur/Bestuurslid | 20-05-2020 | 01-04-2023 |
Hoofd Techniek/Wetenschap/O&O | 01-06-2019 | 01-04-2023 | |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 | 01-07-2018 |
BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01-02-2015 | 01-03-2016 |
PROSENSA HOLDING NV | Hoofd Techniek/Wetenschap/O&O | 01-05-2009 | 01-01-2016 |
PEPGEN INC. | Oprichter | 26-03-2018 | - |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Oprichter | - | - |
Opleiding van Giles Campion
University of Bristol | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 5 |
Verenigde Staten | 3 |
Nederland | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Founder | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
SILENCE THERAPEUTICS PLC | Commercial Services |
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
PEPGEN INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Prosensa Holding NV
Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Albumedix Ltd.
Albumedix Ltd. BiotechnologyHealth Technology Part of Sartorius AG, Albumedix Ltd. is a British science-driven company and recognized leader of albumin-enabled solutions. The company, based in Nottingham, UK, was founded in 1984 with a mission to empower excellence. Albumedix has supported its life-science partners in delivering safe doses of clinical and marketed therapeutics. The company's solutions include the world's only USP-NF compliant recombinant human albumin, client-centric development and compliance services, and drug-enhancing technologies. By challenging the status quo and striving for more, Albumedix enables the development and commercialization of advanced therapies and next-generation biopharmaceuticals. Albumedix is the world leader in recombinant human albumin and has developed a portfolio of products known as Recombumin®. Founded in 1973, the CEO of Albumedix is Jonas S. Moller. The company was acquired by Sartorius Stedim Biotech SA on September 30, 2022, for $500.47 million. | Health Technology |
Pepgen Ltd.
Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Technology Services |
- Beurs
- Insiders
- Giles Campion
- Ervaring